Neuronetics Reports Second Quarter 2022 Financial and Operating Results
Neuronetics (NASDAQ: STIM) reported Q2 2022 revenue of $16.3 million, exceeding guidance of $15.0 million to $16.0 million. This marks a 15% increase from Q2 2021, driven by a 70% rise in NeuroStar System sales, achieving a record 59 systems sold. Operationally, the company secured FDA clearance for treating OCD and anxious depression, and forged a long-term partnership with Alleviant Health Centers. However, net loss rose to $10.4 million, and international revenues fell by 50%. For 2022, revenue guidance is set between $60.0 million and $62.0 million.
- Revenue of $16.3 million exceeded guidance of $15.0 million to $16.0 million.
- NeuroStar System revenue surged 70% year-over-year.
- Sold 59 NeuroStar Systems, a 64% increase from Q2 2021.
- Achieved FDA clearance for OCD and anxious depression treatments.
- Entered a long-term exclusive partnership with Alleviant Health Centers.
- Net loss increased to $10.4 million from $7.5 million year-over-year.
- International revenue decreased by 50% compared to the prior year.
- Gross margin dropped to 75.3%, down from 80.6% in Q2 2021.
- Operating expenses rose by 23% to $22.1 million.
MALVERN, Pa., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced its financial and operating results for the second quarter of 2022.
Second Quarter 2022 Highlights
- Exceeded guidance – Second quarter 2022 revenue of
$16.3 million , exceeded previously issued guidance of$15.0 million to$16.0 million - Increased NeuroStar System revenue
70% over the second quarter of 2021 - Revenue from 59 NeuroStar Systems during the second quarter, an increase of
64% over the second quarter of 2021 - Second quarter 2022 system revenue increased
20% sequentially as compared to first quarter 2022
Recent Operational Highlights
- Received FDA 510(k) clearance for obsessive-compulsive disorder (OCD)
- Received FDA 510(k) clearance for the treatment of anxiety symptoms in patients who suffer from major depressive disorder (MDD), also known as anxious depression
- Positive TMS coverage policies to expand patient access to our NeuroStar Advanced Therapy system for both MDD and OCD
- Entered into long-term exclusive commercial partnership agreement with Alleviant Health Centers
Recent Marketing Highlights
- Achieved over 134,300 global patients treated with more than 4.8 million of our Treatment Sessions and over 5,360 new patient starts in the quarter, a Company record
- Data published in Brain Stimulation Journal highlighted breakthrough treatment protocol insights attained from Neuronetics’ industry leading TrakStar clinical outcomes database
“I am very pleased with our performance throughout the second quarter and first half of the year. We successfully worked through macro challenges and have continued to execute, highlighted by very strong capital system sales volumes and improving utilization along with achieving multiple significant milestones, including the FDA approval for OCD and anxious depression, receiving multiple favorable reimbursement decisions, and expanding the number of exclusive commercial partnerships with national accounts,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. “For the remainder of the year, we will look to leverage the momentum we have built to continue to accelerate our growth and help more patients suffering from mental health disorders get the relief that deserve.”
Second Quarter 2022 Financial and Operating Results for the Three Months Ended June 30, 2022
| Revenues by Geography | ||||||||||
| Three Months Ended June 30, | ||||||||||
| 2022 | 2021 | |||||||||
| Amount | Amount | % Change | ||||||||
| (in thousands, except percentages) | ||||||||||
| United States | $ | 16,132 | $ | 13,809 | 17 | % | ||||
| International | 197 | 394 | (50 | ) | % | |||||
| Total revenues | $ | 16,329 | $ | 14,203 | 15 | % | ||||
Total revenue for the three months ended June 30, 2022, was
| U.S. Revenues by Product Category | |||||||||
| Three Months Ended June 30, | |||||||||
| 2022 | 2021 | ||||||||
| Amount | Amount | % Change | |||||||
| (in thousands, except percentages) | |||||||||
| NeuroStar Advanced Therapy System | $ | 4,382 | $ | 2,577 | 70 | % | |||
| Treatment sessions | 11,295 | 10,801 | 5 | % | |||||
| Other | 455 | 431 | 6 | % | |||||
| Total U.S. revenues | $ | 16,132 | $ | 13,809 | 17 | % | |||
U.S. NeuroStar Advanced Therapy System revenue for the three months ended June 30, 2022, was
U.S. treatment session revenue for the three months ended June 30, 2022, was
In the second quarter of 2022, U.S. treatment session revenue per active site was
Gross margin for the second quarter of 2022 was
Operating expenses during the second quarter of 2022 were
Net loss for the second quarter of 2022 was
EBITDA for the second quarter of 2022 was
Cash and cash equivalents were
510(k) Clearance for Treatment of Adult OCD and Anxious Depression
OCD
In May of 2022, the U.S. Food and Drug Administration (FDA) granted clearance for NeuroStar as an adjunct treatment for adult patients suffering from OCD. NeuroStar has initiated a limited, exclusive launch at centers across the United States and expects to begin training the broader installed base in the fourth quarter of 2022. Importantly, this new indication can be remotely activated on the customer’s existing NeuroStar hardware enabling NeuroStar to treat even more patients suffering from debilitating mental health disorders. In the United States, over 4 million adults suffer from OCD and approximately half of those patients have serious impairment.
Anxious Depression
NeuroStar has successfully leveraged real-world data from its proprietary database of patient outcomes, TrakStar, to gain clearance for a new indication with the FDA. In July of 2022, the FDA granted a new indication for NeuroStar to treat anxiety symptoms in adults with major depressive disorder (MDD), also known as anxious depression. Our submission utilized data collected from 644 patients treated at 75 centers across the country and showed that
Long Term Commercial Partnerships
Alleviant Health Centers
In June of 2022, the Company initiated a commercial partnership with Alleviant Health Centers, an Arkansas-based network of full-service mental health clinics. Under the agreement, Neuronetics will be the exclusive supplier of new TMS equipment to Alleviant and its affiliates. Alleviant had been using a different TMS device prior to our partnership but with plans to expand their footprint across multiple states, they chose NeuroStar because our ongoing support, training and marketing initiatives will be integral to their growth and continued success.
Positive TMS Coverage Policies
In July of 2022, the Company announced a series of healthcare policy updates that increase patient access to NeuroStar Advanced Therapy for TMS. First Coast and Novitas Medicare Administrative Contractors (MACs) have proposed policy updates to local coverage determination (LCD) that would reduce the number of prior medication failures for TMS eligibility from four down to one for people suffering from major depressive disorder (MDD). An additional proposed change would remove the requirement for a previous psychotherapy trial. First Coast coverage area includes two million Medicare beneficiaries, more than 74,000 physicians and 247 hospitals that serve Medicare patients in FL, PR and USVI. Novitas coverage includes over eight million covered lives in CO, NM, TX, OK, AR, LA, MS, PA, NJ, MD, DE, and DC.
Additional positive coverage policies applicable to TMS were recently issued by Highmark BCBS, publishing coverage for obsessive-compulsive disorder (OCD), affecting 6.8 million members in DE, NY, PA, & WV; Select Health, publishing their first TMS policy for MDD, impacting 981,000 members in UT, ID & NV; and Pacific Source removing the MDD pre-authorization requirement for their Medicare Advantage plan members in OR, MT, ID & WA.
Business Outlook
For the full year 2022, the Company now expects total worldwide revenue to be between
For the full year 2022, the Company now expects total operating expenses to be between
For the third quarter of 2022, the Company expects to report total worldwide revenue of between
Webcast and Conference Call Information
Neuronetics’ management team will host a conference call on August 2, 2022, beginning at 8:30 a.m. Eastern Time.
To listen to the conference call on your telephone, participants may register for the call via this link https://register.vevent.com/register/BI4b00043a886241ebb671ea828194825d. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Neuronetics’ website at ir.neuronetics.com. The replay will be available on the Company’s website.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience and the largest transcranial magnetic stimulation (“TMS”) company in the industry, Neuronetics is redefining patient and physician expectations by designing and developing products that improve the quality of life for people suffering from neurohealth conditions. An FDA-cleared, non-drug, noninvasive treatment for people with depression, Neuronetics’ NeuroStar® Advanced Therapy system is the leading TMS treatment for major depressive disorder (“MDD”) in adults with over 4.8 million treatments delivered. NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Our NeuroStar® Advanced Therapy system is also FDA-cleared to treat people suffering from obsessive-compulsive disorder, as well as for the treatment of comorbid anxiety symptoms (“anxious depression”) for adults with MDD suffering from anxiety symptoms. Neuronetics is committed to transforming lives by offering an exceptional treatment option that aims to produce extraordinary results. For safety information and indications for use, visit NeuroStar.com.
“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:
Statements in the press release regarding Neuronetics, Inc. (the “Company”) that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “outlook,” “potential,” “believe,” “expect,” “plan,” “anticipate,” “predict,” “may,” “will,” “could,” “would” and “should” as well as the negative of these terms and similar expressions. These statements include those relating to the Company’s business outlook and current expectations for upcoming quarter and fiscal year 2022, including with respect to revenue, operating expense, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the impact of COVID 19 on the Company’s operational and budget plans as well as general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID 19, such as travel restrictions and third-party business closures and the related impact on resource allocations, manufacturing and supply chains and patient access to commercial products; the Company’s ability to execute its business continuity; the Company’s ability to achieve or sustain profitable operations due to its history of losses; the Company’s reliance on the sale and usage of its NeuroStar Advanced Therapy for Mental Health System to generate revenues; the scale and efficacy of the Company’s salesforce as well as the Company’s ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using the Company’s products; physician and patient demand for treatments using the Company’s products; developments in respect of competing technologies and therapies for the indications that the Company’s products treat; product defects; the Company’s ability to obtain and maintain intellectual property protection for its technology; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy for Mental Health System for additional indications; and developments in regulation in the United States and other applicable jurisdictions. For a discussion of these and other related risks, please refer to the Company’s recent SEC filings which are available on the SEC’s website at www.sec.gov. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.
Investor Contact:
Mike Vallie or Mark Klausner
Westwicke Partners
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
NEURONETICS, INC.
Statements of Operations
(In thousands, except per share data)
| Three Months ended | Six months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenues | $ | 16,329 | $ | 14,203 | $ | 30,510 | $ | 26,491 | ||||||||
| Cost of revenues | 4,039 | 2,750 | 7,524 | 4,971 | ||||||||||||
| Gross Profit | 12,290 | 11,453 | 22,986 | 21,520 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Sales and marketing | 13,685 | 9,042 | 26,334 | 17,604 | ||||||||||||
| General and administrative | 6,356 | 6,681 | 12,734 | 12,785 | ||||||||||||
| Research and development | 2,045 | 2,294 | 3,849 | 4,604 | ||||||||||||
| Total operating expenses | 22,086 | 18,017 | 42,917 | 34,993 | ||||||||||||
| Loss from Operations | (9,796 | ) | (6,564 | ) | (19,931 | ) | (13,473 | ) | ||||||||
| Other (income) expense: | ||||||||||||||||
| Interest expense | 1,000 | 977 | 1,978 | 1,962 | ||||||||||||
| Other income, net | (374 | ) | (16 | ) | (649 | ) | (29 | ) | ||||||||
| Net Loss | $ | (10,422 | ) | $ | (7,525 | ) | $ | (21,260 | ) | $ | (15,406 | ) | ||||
| Net loss per share of common stock outstanding, basic and diluted | $ | (0.39 | ) | $ | (0.29 | ) | $ | (0.80 | ) | $ | (0.63 | ) | ||||
| Weighted-average common shares outstanding, basic and diluted | 26,787 | 25,903 | 26,692 | 24,608 | ||||||||||||
NEURONETICS, INC.
Balance Sheets
(In thousands, except per share data)
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 70,931 | $ | 94,141 | ||||
| Accounts receivable, net | 11,391 | 7,706 | ||||||
| Inventory | 7,185 | 6,563 | ||||||
| Current portion of net investments in sales-type leases | 2,096 | 2,198 | ||||||
| Current portion of prepaid commission expense | 1,768 | 1,559 | ||||||
| Current portion of note receivables | 95 | 74 | ||||||
| Prepaid expenses and other current assets | 1,618 | 3,090 | ||||||
| Total current assets | 95,084 | 115,331 | ||||||
| Property and equipment, net | 2,067 | 1,220 | ||||||
| Operating lease right-of-use assets | 3,614 | 3,884 | ||||||
| Net investments in sales-type leases | 1,682 | 1,697 | ||||||
| Prepaid commission expense | 7,163 | 6,763 | ||||||
| Long-term note receivable | 10,089 | 10,110 | ||||||
| Other assets | 3,254 | 2,218 | ||||||
| Total Assets | $ | 122,953 | $ | 141,223 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,350 | $ | 4,299 | ||||
| Accrued expenses | 9,684 | 8,233 | ||||||
| Deferred revenue | 1,748 | 2,501 | ||||||
| Current portion of operating lease liabilities | 780 | 670 | ||||||
| Current portion of long-term debt, net | 4,375 | — | ||||||
| Total current liabilities | 18,937 | 15,703 | ||||||
| Long-term debt, net | 31,210 | 35,335 | ||||||
| Deferred revenue | 1,129 | 1,471 | ||||||
| Operating lease liabilities | 3,255 | 3,539 | ||||||
| Total Liabilities | 54,531 | 56,048 | ||||||
| Commitments and contingencies (Note 17) | — | — | ||||||
| Stockholders’ Equity: | ||||||||
| Preferred stock, | ||||||||
| outstanding on June 30, 2022, and December 31, 2021 | — | — | ||||||
| Common stock, | ||||||||
| shares issued and outstanding on June 30, 2022, and December 31, 2021, respectively | 268 | 264 | ||||||
| Additional paid-in capital | 398,147 | 393,644 | ||||||
| Accumulated deficit | (329,993 | ) | (308,733 | ) | ||||
| Total Stockholders’ Equity | 68,422 | 85,175 | ||||||
| Total Liabilities and Stockholders’ Equity | $ | 122,953 | $ | 141,223 | ||||
NEURONETICS, INC.
Statements of Cash Flows
(In thousands)
| Six months ended June 30, | ||||||||
| 2022 | 2021 | |||||||
| Cash Flows from Operating Activities: | ||||||||
| Net loss | $ | (21,260 | ) | $ | (15,406 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 657 | 552 | ||||||
| Share-based compensation | 4,455 | 4,205 | ||||||
| Non-cash interest expense | 340 | 324 | ||||||
| Cost of rental units purchased by customers | 92 | 137 | ||||||
| Changes in certain assets and liabilities: | ||||||||
| Accounts receivable, net | (3,685 | ) | (1,835 | ) | ||||
| Inventory | (840 | ) | (1,673 | ) | ||||
| Net investment in sales-type leases | 102 | 330 | ||||||
| Prepaid commission expense | (610 | ) | (278 | ) | ||||
| Prepaid expenses and other assets | 1,517 | 1,120 | ||||||
| Accounts payable | (2,256 | ) | (1,365 | ) | ||||
| Accrued expenses | 1,451 | (715 | ) | |||||
| Deferred revenue | (1,095 | ) | (336 | ) | ||||
| Net Cash Used in Operating Activities | (21,132 | ) | (14,940 | ) | ||||
| Cash Flows from Investing Activities: | ||||||||
| Purchases of property and equipment and capitalized software | (2,040 | ) | (1,108 | ) | ||||
| Net Cash Used in Investing Activities | (2,040 | ) | (1,108 | ) | ||||
| Cash Flows from Financing Activities: | ||||||||
| Payments of debt issuance costs | (90 | ) | — | |||||
| Proceeds from exercises of stock options | 52 | 2,303 | ||||||
| Proceeds from common stock offering | — | 80,972 | ||||||
| Payments of common stock offering issuance costs | — | (401 | ) | |||||
| Net Cash (Used) Provided by Financing Activities | (38 | ) | 82,874 | |||||
| Net (Decrease) Increase in Cash and Cash Equivalents | (23,210 | ) | 66,826 | |||||
| Cash and Cash Equivalents, Beginning of Period | 94,141 | 48,957 | ||||||
| Cash and Cash Equivalents, End of Period | $ | 70,931 | $ | 115,783 | ||||
Non-GAAP Financial Measures (Unaudited)
EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States, or GAAP, and should not be construed as a substitute for, or superior to, GAAP net loss. However, management uses both the GAAP and non-GAAP financial measures internally to evaluate and manage the Company’s operations and to better understand its business. Further, management believes the addition of the non-GAAP financial measure provides meaningful supplementary information to, and facilitates analysis by, investors in evaluating the Company’s financial performance, results of operations and trends. The Company’s calculation of EBITDA may not be comparable to similarly designated measures reported by other companies, because companies and investors may differ as to what type of events warrant adjustment.
The following table reconciles reported net loss to EBITDA:
| Three Months ended | Six months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||
| Net loss | $ | (10,422 | ) | $ | (7,525 | ) | $ | (21,260 | ) | $ | (15,406 | ) | ||||
| Interest expense | 1,000 | 977 | 1,978 | 1,962 | ||||||||||||
| Income taxes | — | — | — | — | ||||||||||||
| Depreciation and amortization | 338 | 271 | 657 | 552 | ||||||||||||
| EBITDA | $ | (9,084 | ) | $ | (6,277 | ) | $ | (18,625 | ) | $ | (12,892 | ) | ||||
FAQ
What were Neuronetics' Q2 2022 revenue results?
What is the stock symbol for Neuronetics?
What FDA clearances did Neuronetics receive recently?
How much did Neuronetics' net loss increase in Q2 2022?
What is Neuronetics' revenue guidance for full-year 2022?
